However, it was the late-breaking Phase 1/2 data from the SOHO-01 study of sevabertinib (BAY 2927088) in advanced HER2-mutant ...

GSK and Spero Therapeutics' oral cabapenem, tebipenem HBr, has become the first antibiotic in the class to show efficacy in a ...

The company ended the first half of this year with €3.1 billion ($3.6 billion) in cash reserves, and is due to report its ...

Novo Nordisk's chairman Helge Lund and several other independent board members have indicated they will step down next month, ...

Hevia and Sousa discuss the landscape of unmet needs in metastatic castration-resistant prostate cancer, what the new data ...

Alex and Schnappauf explain how Vault CRM is a step-change for companies like Bayer, and discuss the benefits of being able ...

Roche has taken a lead in the oral SERD category of breast cancer therapies with the presentation of new data at ESMO showing ...

AstraZeneca and Daiichi Sankyo's Datroway (datopotamab deruxtecan) came out of the blocks strongly at the ESMO congress with ...

On Friday 17th October, the European Society for Medical Oncology’s Annual Meeting 2025 kicked off, with the opening press ...

Insmed's DPP1 inhibitor Brinsupri (brensocatib) has been recommended by the CHMP for the treatment of patients aged 12 and ...

Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP ...